The FBXO30 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, designed to create a loss-of-function model for the F-box protein FBXO30 in Homo sapiens. This polyclonal knockout product enables robust investigation of FBXO30-mediated ubiquitination and its regulatory roles in cellular processes, utilizing CRISPR/Cas9-mediated gene disruption to eliminate functional FBXO30 expression across a heterogeneous pool of cells, thereby providing a versatile tool for pathway analysis and drug response profiling in a physiologically relevant B-cell context.
The host Raji cell line originates from a Burkitt’s lymphoma patient, characterized as an Epstein-Barr virus (EBV)-positive suspension B lymphocyte culture. Raji cells are widely employed in immunology and hematological malignancy research due to their capacity for antibody production and their representation of B-cell neoplasia. The EBV-immortalized background offers a unique platform to study viral interactions with cellular ubiquitin-proteasome pathways, and the suspension growth format facilitates scalable experimental workflows for high-throughput screening and functional genomics studies.
FBXO30 functions as the substrate recognition subunit of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex, interacting with SKP1, CUL1, and RBX1 to target specific proteins for ubiquitination and subsequent proteasomal degradation. Among its validated downstream targets, FBXO30 directly mediates the ubiquitination of Cyclin D1 (CCND1) and Poly(ADP-ribose) polymerase 1 (PARP1), thereby controlling cell cycle progression through G1/S transition and modulating DNA damage repair and apoptosis. FBXO30 activity is regulated upstream by DNA damage signaling and cellular stress cues, linking genome integrity surveillance to proteome homeostasis, and its dysregulation is implicated in oncogenic transformation and neurodegeneration.
In the Raji B-lymphocyte system, FBXO30 knockout provides a clinically relevant model to dissect the molecular underpinnings of B-cell malignancies. The EBV-positive lymphoma background allows researchers to examine how loss of FBXO30-mediated degradation of Cyclin D1 and PARP1 affects proliferation rates, apoptotic thresholds, and responses to genotoxic agents. This model can uncover FBXO30-dependent vulnerabilities in lymphomagenesis and contribute to understanding how ubiquitin ligase alterations drive hematological cancers, while also enabling investigation of the interplay between viral latency and host cell cycle regulation.
The FBXO30 Knockout Raji Polyclonal Cells are ideally suited for a broad range of advanced biomedical research applications, including mechanistic studies of ubiquitin-proteasome system dynamics, cell cycle checkpoint regulation, DNA damage response signaling, and cancer biology. These cells support experimental techniques such as Western blotting for FBXO30, Cyclin D1, and PARP1; RT-qPCR; flow cytometry for cell cycle and apoptosis analysis; co-immunoprecipitation to detect ubiquitination events; cycloheximide chase assays for protein stability; PARP1 activity measurements; phospho-H2AX-based DNA damage assessment; and drug sensitivity profiling. For further information or to discuss your specific experimental needs, please contact Ascent Research.
